文献速递消化内镜

1升聚乙二醇联合抗坏血酸加利那洛肽与番泻叶用于肠道准备的疗效:多中心、内镜医师设盲、随机对照试验(Apple试验)

Efficacy of 1 L Polyethylene Glycol Plus Ascorbic Acid With Linaclotide Versus Senna for Bowel Preparation: A Multicenter, Endoscopist-Blinded, Randomized Controlled Trial (Apple Trial).
PubMed 文献 · Am J Gastroenterol · 2025-02-25

在日本5个中心开展的多中心、内镜医师设盲、随机对照试验纳入1464例门诊结肠镜检查患者,比较1升聚乙二醇联合抗坏血酸(PEG-Asc)分别加入利那洛肽0.5 mg(1L-PEG/AL组731例)或番泻叶24 mg(1L-PEG/AS组733例)的肠道准备效果。结果显示1L-PEG/AL组充分肠道准备率高于1L-PEG/AS组(92% vs 86%,P=0.001),在高风险患者中差异更明显(94% vs 86%,P<0.001),两组不良事件相似且重复肠道准备意愿均较高。

要点

  • 1L-PEG/AL组充分肠道准备率92%,高于1L-PEG/AS组的86%(P=0.001)。
  • 高风险患者中1L-PEG/AL组充分准备率94%,高于1L-PEG/AS组的86%(P<0.001)。
  • 两组不良事件相似,重复肠道准备意愿分别为83%和81%(P=0.49)。

核心结论

  • 利那洛肽方案在肠道准备疗效方面优于番泻叶方案,且未降低耐受性。
  • 利那洛肽方案可能成为肠道准备的新选择,尤其适用于肠道准备不充分高风险患者。

研究设计与样本

  • 多中心、内镜医师设盲、随机对照试验,在日本5个中心开展,纳入计划行结肠镜检查的门诊患者。
  • 共随机分配1464例患者至1L-PEG/AL组(n=731)或1L-PEG/AS组(n=733)。
  • 主要终点为采用波士顿肠道准备量表评估的充分肠道准备,分析按肠道准备不充分低风险和高风险组进行分层。

主要发现

  • 2022年4月至2023年4月期间随机分配1464例患者。
  • 1L-PEG/AL组充分肠道准备率为92%,1L-PEG/AS组为86%(P=0.001)。
  • 高风险患者(n=892)中,1L-PEG/AL组充分肠道准备率为94%,1L-PEG/AS组为86%(P<0.001)。
  • 低风险患者(n=539)中,两组充分肠道准备率均为94%(P=0.66)。
  • 两组不良事件相似,重复肠道准备意愿分别为83%和81%(P=0.49)。

临床怎么用

  • 作者认为利那洛肽方案在肠道准备疗效方面优于番泻叶方案且未降低耐受性,可能成为肠道准备的新选择,尤其适用于肠道准备不充分高风险患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: No bowel preparation (BP) for colonoscopy achieves optimal efficacy and tolerability. Combining polyethylene glycol plus ascorbic acid (PEG-Asc) with adjuvants has been explored to enhance cleansing efficacy and reduce the required volume. The aim of this study was to evaluate whether adding 0.5 mg linaclotide to 1 L PEG-Asc (1 L-PEG/AL) improves superior cleansing compared with adding 24 mg senna (1 L-PEG/AS), which we previously reported to be noninferior to the standard regimen of 2 L PEG-Asc. METHODS: A multicenter, endoscopist-blinded, randomized controlled trial was conducted at 5 centers in Japan with outpatients scheduled for colonoscopy. The primary outcome was adequate BP, evaluated using the Boston Bowel Preparation Scale. Analyses were stratified based on low-risk and high-risk groups for inadequate BP. RESULTS: Between April 2022 and April 2023, 1,464 patients were randomized to the 1L-PEG/AL (n = 731) or 1L-PEG/AS (n = 733). The 1L-PEG/AL demonstrated higher adequate BP rates (92% vs 86%, P = 0.001) compared with 1L-PEG/AS. Both groups experienced similar adverse events and expressed high willingness for repeat BP (83% vs 81%, P = 0.49). In high-risk patients (n = 892), 1L-PEG/AL had significantly higher adequate BP rates (94% vs 86%, P < 0.001), whereas rates were comparably high in low-risk patients (n = 539) (94% vs 94%, P = 0.66). DISCUSSION: The linaclotide regimen was superior to the senna regimen reagrding BP efficacy without reducing tolerability. It can be a promising new option for BP, especially in patients at a high risk of inadequate BP.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Maeda N, Higashimori A, Kabata D, et al. Efficacy of 1 L Polyethylene Glycol Plus Ascorbic Acid With Linaclotide Versus Senna for Bowel Preparation: A Multicenter, Endoscopist-Blinded, Randomized Controlled Trial (Apple Trial). Am J Gastroenterol. 2025. PMID: 39996602. doi:10.14309/ajg.0000000000003370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。